Updated July 2026 · 7 min read

Tumor Lysis Syndrome for ICU Nurses 2026 — When Dying Cancer Cells Poison the Blood

Part of the ICU Emergencies Hub — browse every related guide in one place.

Tumor lysis syndrome (TLS) is what happens when a large, fast-growing cancer breaks apart — usually after chemotherapy, sometimes on its own — and dumps the entire contents of millions of cells into the bloodstream faster than the kidneys can clear them. The result is a distinctive, dangerous metabolic picture: potassium and phosphate soar, uric acid climbs, and calcium falls. It is one of the true oncologic emergencies, and it can trigger fatal arrhythmias, seizures, and acute kidney failure. For the ICU nurse, TLS is a monitoring and prevention story as much as a treatment one — the patients who do well are the ones caught early and hydrated aggressively.

Why the labs move the way they do

Every cell is a packet of potassium, phosphate, and nucleic acids. When a bulky tumor lyses, that packet spills out all at once. Intracellular potassium pours into the blood, threatening the heart. Intracellular phosphate rises, and the excess phosphate binds circulating calcium, dragging calcium down (secondary hypocalcemia). The nucleic acids are metabolized to uric acid, which climbs and can crystallize in the renal tubules. Meanwhile, calcium-phosphate can also precipitate in the kidney. Two mechanisms — uric acid crystals and calcium-phosphate crystals — converge on the same organ, which is why acute kidney injury both results from TLS and then worsens every other value by reducing clearance.

Who is at risk, and when

The highest-risk patients have a bulky, rapidly dividing, chemo-sensitive cancer — acute leukemias and high-grade lymphomas (such as Burkitt) are classic — and TLS most often erupts within roughly the first one to three days after starting treatment. Pre-existing kidney impairment, dehydration, a high baseline uric acid, and a large tumor burden all raise the risk. Because it is predictable, TLS is heavily prevented: at-risk patients are identified before chemotherapy, pre-hydrated, and started on uric-acid-lowering therapy, then watched with scheduled labs through the danger window. A nurse who knows a patient just started induction chemo for leukemia should already be thinking about TLS.

Prevention and treatment: hydration is the foundation

Aggressive IV fluid is the single most important intervention. Generous hydration keeps a high urine output that flushes uric acid and phosphate through the tubules before they crystallize, so meticulous intake-and-output and hourly urine tracking are core nursing tasks. On top of hydration, uric acid is controlled two ways: allopurinol blocks new uric acid formation (prevention), while rasburicase enzymatically breaks down existing uric acid and works far faster for established or high-risk TLS. Hyperkalemia is treated on its own urgent track, and symptomatic hypocalcemia is corrected cautiously — giving calcium when phosphate is very high can worsen calcium-phosphate deposition, so it is generally reserved for symptoms.

The nursing monitoring that saves the patient

TLS is managed at the bedside through vigilance. Keep the patient on continuous cardiac monitoring and know the ECG signature of hyperkalemia (peaked T waves, widening QRS) and of hypocalcemia (prolonged QT); either can precipitate an arrhythmia. Track scheduled electrolytes, phosphate, calcium, uric acid, and renal function frequently through the risk window, and report a rising potassium or a falling urine output immediately. Watch for the neuromuscular signs of low calcium — tingling, cramps, twitching, tetany, seizures. And recognize the endpoint: when hydration and medication cannot keep up — refractory hyperkalemia, severe symptomatic hypocalcemia, fluid overload, or worsening acute kidney injury — renal replacement therapy is the rescue.

The nursing bottom line

Tumor lysis syndrome is dying tumor cells spilling their contents faster than the kidney can clear them: high potassium, high phosphate, high uric acid, low calcium, and acute kidney injury tying them together. It is largely predictable and therefore largely preventable — identify the high-risk patient starting chemo, pre-hydrate hard, lower uric acid with allopurinol or rasburicase, and monitor labs and the cardiac rhythm relentlessly through the first few days. Guard the G6PD contraindication for rasburicase, keep the urine flowing, treat hyperkalemia on its own emergency track, and know that dialysis is the backstop when the metabolic storm outruns everything else.

Related: Hyperkalemia emergency treatment · Phosphate replacement · CRRT basics · IV magnesium replacement

Educational content for licensed clinicians. Always follow your facility's protocol and provider orders. Not medical advice.